Long-listed products (LLPs) in Japan will be subject to a new health coverage scheme starting this October. This is expected…
HOME > BUSINESS
BUSINESS
- Zeria Terminates Development of Allergic Rhinitis Treatment
October 9, 2012
- Towa Consolidates Distribution Bases to 2 Sites in Eastern and Western Japan
October 9, 2012
- Takeda to Acquire LigoCyte of the US to Strengthen Vaccine Business
October 9, 2012
- Takeda Appeals to IP High Court in Actos Patent Lawsuit
October 9, 2012
- Ono, Carna Biosciences Conclude Capital Alliance Agreement, Making Ono Carna’s Largest Shareholder
October 9, 2012
- GSK’s Requip CR Tablets More Economical and Effective; Sales May Decrease despite Investment in Improved Formulation
October 8, 2012
- All Sawai MRs to Use iPads, First for Generics Maker
October 5, 2012
- Data Acquisition Completed for Anti-HIV Treatment, Submission for Regulatory Approval in US, Europe Planned By Year End: Shionogi
October 5, 2012
- Novartis to See Tasigna Sales More than Double, Value of Glivec Maximized
October 5, 2012
- Kyowa Kirin Files for Approval Based on Public Knowledge for IM Administration and Dosage for Leunase
October 5, 2012
- Ono Conducts Nation’s First Microdosing Study for New Drug Candidate
October 5, 2012
- Bayer Files for Fosrenol for Patients with CKD in Preservation Period
October 5, 2012
- MTPC Outsources All Logistics Operations
October 5, 2012
- Takeda, Lundbeck File NDA for Major Depressive Disorder Treatment Vortioxetine in US
October 4, 2012
- Baxter Files for Approval in Japan for Cell Culture Influenza Vaccine
October 4, 2012
- Takeda Initiates Drug Discovery Collaboration with Advinus of India to Boost Research Productivity
October 4, 2012
- Daiichi Sankyo Discontinues PIII Study of ARQ197 in Patients with NSCLC
October 4, 2012
- Sanofi Takes Over 3 Genzyme Products
October 3, 2012
- Astellas Strikes Deal to License JAK Inhibitor to Janssen Biotech Outside Japan
October 3, 2012
- Seikagaku Completes New Production Facilities for Gel-One to Meet Increasing Demand in US
October 3, 2012
ページ
In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…